IP Verse

Tumor Therapeutic Agent - EP3338779

The patent EP3338779 was granted to Eisai R&D Management on Jun 30, 2021. The application was originally filed on Aug 18, 2016 under application number EP16837150A. The patent is currently recorded with a legal status of "Revoked".

EP3338779

EISAI R&D MANAGEMENT
Application Number
EP16837150A
Filing Date
Aug 18, 2016
Status
Revoked
Aug 30, 2025
Grant Date
Jun 30, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STADA ARZNEIMITTELMar 29, 2022HAMM & WITTKOPPADMISSIBLE

Non-Patent Literature (NPL) Citations (20) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Botter Sander M, Et Al, "Recent advances in osteosarcoma", Current Opinion in Pharmacology, Elsevier, (20140101), vol. 16, pages 15 - 23, XP055910202-
OPPOSITION- Eisai Limited, "History of Changes for Study: NCT02432274 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies", ClinicalTrials.gov, NCBI, pages 1 - 9, ClinicalTrials.gov, URL: https://classic.clinicaltrials.gov/ct2/history/NCT02432274?A=1&B=6&C=merged#StudyPageTop, (20240122), XP093122042-
OPPOSITION- European Medicines Agency Ema, "Assessment report Lenvima. International non-proprietary name: lenvatinib", EMA Procedure No. EMEA/H/C/003727/0000, (20150326), pages 1 - 170, XP055910213-
OPPOSITION- Lehrbuch der Pharmakologie und Toxikologie, (20010000), vol. 8, pages 123 - 124, XP055780128-
OPPOSITION- Lund Walter (ed.), "The Pharmaceutical Codex 12th edition (excerpt)", (19940101), pages 342 - 349, XP055910226-
OPPOSITION- Mutschler E., Geisslinger, Kroemer, A Schäfer-Korting, "10 Arzneimittelentwicklung und -prüfung", Mutschler Arzneimittelwirkungen, Stuttgart, Wissenschaftliche Verlagsgesellschaft mbH , (20010101), pages 120 - 122, XP093119211-
OPPOSITION- Mutschler, Et Al, "Mutschler Arzneimittelwirkungen Lehrbuch der Pharmakologie und Toxikologie. Passage", (20010101), pages 882 - 892, XP055910198-
OPPOSITION- The Esmo/european Sarcoma Network Working Group, "Clinical practice guidelines. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Annals of Oncology, (20140101), vol. 25, no. Supp 3, pages 113 - 123, XP055910206-
OPPOSITION- URL: https://www.clinicaltrials.gov/ct2/history/NCT02432274?V_ 1=View#StudyP ageTop-
OPPOSITION- Skjalg Bruheim; Alexandr Kristian; Toshimitsu Uenaka; Zhenhe Suo; Akihiko Tsuruoka; Jahn M. Nesland; Øystein Fodstad, "Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts", International Journal of Cancer, John Wiley & Sons, Inc., US, US , (20110325), vol. 129, no. 3, doi:10.1002/ijc.25922, ISSN 0020-7136, pages 742 - 750, XP071286240
OPPOSITION- Van Winkle Patrick, Angiolillo Anne, Krailo Mark, Cheung Ying‐kuen, Anderson Barry, Davenport Virginia, Reaman Gregory, Cairo Mitchell S., "Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: The Children's Cancer Group (CCG) experience", PEDIATRIC BLOOD AND CANCER, WILEY, HOBOKEN, NJ, US, US , (20050401), vol. 44, no. 4, doi:10.1002/pbc.20227, ISSN 1545-5009, pages 338 - 347, XP093122054
OPPOSITION- Fleuren Emmy D.G., Versleijen-Jonkers Yvonne M.H., Boerman Otto C., Van Der Graaf Winette T.A., "Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives", Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, ELSEVIER SCIENCE BV, AMSTERDAM., NL, NL , (20140401), vol. 1845, no. 2, doi:10.1016/j.bbcan.2014.02.005, ISSN 0304-419X, pages 266 - 276, XP093119212
OPPOSITION- Marina Neyssa M; Smeland Sigbjørn; Bielack Stefan S; Bernstein Mark; Jovic Gordana; Krailo Mark D; Hook Jane M; Arndt Carola; van den Berg Henk; Brennan Bernadette; Brichard Bénédicte; Brown Ken L B; Butterfass-Bahloul Trude; Calaminus Gabriele; Daldrup-Link Heike E; Eriksson Mikael; Gebhardt Mark C; Gelderblom Hans; Gerss Joachim; Goldsby Robert; Goorin Allen; Gorlick Richard; Grier Holcombe E; Hale Juliet P; Hall Kirsten Sundby; Hardes Jendrik; Hawkins Douglas S; Helmke Knut; Hogendoorn Pancras C W; Isakoff Michael S; Janeway Katherine A; Jürgens Heribert; Kager Leo; Kühne Thomas; Lau Ching C; Leavey Patrick J; Lessnick Stephen L; Mascarenhas Leo; Meyers Paul A; Mottl Hubert; Nathrath Michaela; Papai Zsuzsanna; Randall R Lor; Reichardt Peter; Renard Marleen; Safwat Akmal Ahmed; Schwartz Cindy L; Stevens Michael C G; Strauss Sandra J; Teot Lisa; Werner Mathias; Sydes Matthew R; Whelan Jeremy S, "Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL , (20160825), vol. 17, no. 10, doi:10.1016/S1470-2045(16)30214-5, pages 1396 - 1408, XP029757492
OPPOSITION- Gaspar Nathalie; Venkatramani Rajkumar; Hecker-Nolting Stefanie; Melcon Soledad Gallego; Locatelli Franco; Bautista Francisco; Longhi Alessandra; Lervat Cyril; Entz-Werle Natacha; Casanova Michela; Aerts Isabelle; Strauss Sandra J; Thebaud Estelle; Morland Bruce; Nieto Adela Cañete; Marec-Berard Perrine; Gambart Marion; Rossig Claudia; Okpara Chinyere E; He Cixin; Dutta Lea; Campbell-Hewson Quentin, "Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL , (20210817), vol. 22, no. 9, doi:10.1016/S1470-2045(21)00387-9, pages 1312 - 1321, XP086760241
OPPOSITION- Gaspar Nathalie, Venkatramani Rajkumar, Hecker-Nolting Stefanie, Melcon Soledad Gallego, Locatelli Franco, Bautista Francisco, Longhi Alessandra, Lervat Cyril, Entz-Werle Natacha, Casanova Michela, Aerts Isabelle, Strauss Sandra J, Thebaud Estelle, Morland Bruce, Nieto Adela Cañete, Marec-Berard Perrine, Gambart Marion, Rossig Claudia, Okpara Chinyere E, He Cixin, Dutta Lea, Campbell-Hewson Quentin, "Supplementary Material Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20210901), vol. 22, no. 9, doi:10.1016/S1470-2045(21)00387-9, ISSN 1470-2045, pages 1312 - 1321, XP093122051
OPPOSITION- Whelan J.S., Bielack S.S., Marina N., Smeland S., Jovic G., Hook J.M., Krailo M., Anninga J., Butterfass-Bahloul T., Böhling T., Calaminus G., Capra M., Deffenbaugh C., Dhooge C., Eriksson M., Flanagan A.M., Gelderblom H., Goorin A., Gorlick R., Gosheger G., Grimer R.J., Hall K.S., Helmke K., Hogendoorn P.C.W., Jundt G., Kager L., Kuehne T., Lau C.C., Letson G.D., Meyer J., Meyers P.A., Morris C., Mottl H., Nadel H., Nagarajan R., Randall R.L., Schomberg P., Schwarz R., Teot L.A., Sydes M.R., Bernstein M., Pickering James, Joffe Nicola, Kevric Matthias, Sorg Benjamin, Villaluna Doojduen, Wang Caroline, Perisoglou Martha, Trani Leonardo, Potratz Jenny, Carrle Dorothe, Wilhelm Miriam, Zils Katja, Teske Carmen, "EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment", Annals of Oncology, (20150201), vol. 26, no. 2, doi:10.1093/annonc/mdu526, ISSN 0923-7534, pages 407 - 414, XP093122043
OPPOSITION- Matsuki Masahiro; Okamoto Kiyoshi; Dezso Zoltan; Agoulnik Sergei I; Funahashi Yasuhiro; Matsui Junji, "Antitumor activity of a combination of lenvatinib mesilate, ifosfamide, and etoposide against human pediatric osteosarcoma cell lines", Cancer research, American Association for Cancer Research, US, (20160630), vol. 76, no. Suppl. 14, doi:10.1158/1538-7445.AM2016-3266, ISSN 0008-5472, page 3266, XP009511737
SEARCH- BRUHEIM SKJALG ET AL, "Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts", INTERNATIONAL JOURNAL OF CANCER, (201108), vol. 129, no. 3, pages 742 - 750, XP002789540 [A] 1-12 * abstract *
SEARCH- MATSUKI MASAHIRO ET AL, "Antitumor activity of a combination of lenvatinib mesilate, ifosfamide, and etoposide against human pediatric osteosarcoma cell lines", CANCER RESEARCH; 107TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-OF-CANCER-RESEARCH (AACR), AMERICAN ASSOCIATION FOR CANCER RESEARCH, US; NEW ORLEANS, LA, USA, (20160630), vol. 76, no. Suppl. 14, doi:10.1158/1538-7445.AM2016-3266, ISSN 0008-5472, page 3266, XP009511737 [XP] 1-6 * abstract *
SEARCH- GOORIN ALLEN M ET AL, "Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 15 JAN 2002, (20020115), vol. 20, no. 2, ISSN 0732-183X, pages 426 - 433, XP009511743 [A] 1-12 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents